NTP42
Pulmonary Arterial Hypertension (PAH)
Key Facts
About ATXA Therapeutics
ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.
View full company profileAbout ATXA Therapeutics
ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.
View full company profileAbout ATXA Therapeutics
ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.
View full company profileAbout ATXA Therapeutics
ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.
View full company profileAbout ATXA Therapeutics
ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia | Approved |
| LIQ861 (treprostinil) inhalation powder | Liquidia | Phase 3 |
| L606 (liposomal treprostinil) injection | Liquidia | Preclinical |
| Transdermal Treprostinil Prodrug Patch | Corsair Pharma | Pre-clinical |
| Anti-EMAP II monoclonal antibody | Allinaire Therapeutics | Pre-clinical |
| Tiprelestat | tiakis Biotech | Phase 2 |
| Seralutinib | Chiesi | Phase 3 |
| Sotatercept | Merck | Phase 3 |
| TPIP (Treprostinil Palmitil Inhalation Powder) | Insmed | Phase 2b |
| Ralinepag | United Therapeutics | Phase 3 |
| Beraprost MR | United Therapeutics | Phase 3 |
| CS1 | Cereno Scientific | Phase II |